Navigation Links
BioMS Medical Announces 2008 Year End Results
Date:3/17/2009

42,492 --------------------- 100,504 51,410 --------------------- --------------------- BioMS Medical Corp. (A Development Stage Corporation) Consolidated Statements of Operations and Comprehensive Loss ------------------------------------------------------------------------- (expressed in thousands of Canadian dollars and shares, except per share amounts) Cumulative from inception to Years December 31, ended December 31, ------------ ------------------- 2008 2008 2007 $ $ $ Research and development Revenue earned from collaboration partner 52,561 52,561 - Research and development expenses (152,085) (46,502) (38,907) ------------ ------------------- (99,524) 6,059 (38,907) General and administrative expenses (42,605) (13,790) (7,490) Amortization of licensing costs (11,755) (1,472) (1,472) Amortization of property and equipment (517) (125) (134) ------------ ------------------- Loss from operations (154,401) (9,328) (48,003) Other income (expense) Investment income 8,779 2,436 1,644 Foreign exchange gain (loss)
'/>"/>
SOURCE BioMS Medical Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. BioMS Medical warrant extension
2. BioMS Medical to present at BIO CEO and Investor Conference
3. BioMS Medical reports results of exploratory phase II trial of dirucotide in relapsing remitting multiple sclerosis
4. BioMS Medical recognized at Scrip Awards 2008
5. BioMS Medical Announces Third Quarter 2008 Results
6. BioMS Medical to present at Rodman and Renshaw Annual Healthcare Conference
7. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
9. BioMS Medical announces receipt of milestone payment from Eli Lilly and Company
10. BioMS Medical to present at Sachs Associates Biotech in Europe Forum
11. BioMS Medical to present at UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... SEATTLE , April 1, 2015  Adaptive ... The Lancet Oncology showing ... the company,s next-generation sequencing-based minimal residual disease (MRD) ... clonoSEQ™ MRD test) accurately identifies patients with diffuse ... of relapse after initial treatment, usually several months ...
(Date:4/1/2015)... (PRWEB) April 01, 2015 ... (AFM) was selected to receive the prestigious “Best ... Economy Magazine.    Park NX10 is the premium research-grade True ... Z scanner linearity, closed-loop detector noise, and minimized ... SmartSca n, which allows images with a ...
(Date:4/1/2015)... April 1, 2015 /PRNewswire/ - Portage Biotech Inc. ... is pleased to announce that Biohaven Pharmaceutical Holding ... has entered into an agreement with inVentiv Health ... trial with their lead compound (BHV-0223). ... development of clinical stage neuroscience compounds targeting the ...
(Date:4/1/2015)... 1, 2015  Among 1,050 U.S. consumers, the majority ... (68 percent) and only 36 percent reported being screened ... to findings from a survey released today ... and developer of solutions that aid in the early ... survey polled 1,050 U.S. consumers on their knowledge of ...
Breaking Biology Technology:Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 3Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 4Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 5Park Systems Awarded the New Economy Magazine “Best Analytic Instrumentation Company 2014” 2Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 2National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 4
... VRML ) announced that on February 22, 2008 it ... indicated the Company is not in,compliance with Marketplace Rule ... $2,500,000 in stockholders, equity; (ii) $35,000,000 in market,value of ... continuing,operations for the most recently completed fiscal year or ...
... SAN DIEGO, Feb. 27 Arena Pharmaceuticals,Inc. (Nasdaq: ... quarter,and full year ended December 31, 2007., Total ... million,compared to $4.7 million in the fourth quarter of ... 2007 were $19.3 million, compared to $30.6,million in the ...
... Feb. 27 DARA BioSciences(TM),(Nasdaq: DARA ) announced ... Board of Directors. Mr. Cochrane was appointed to fill ... and Compensation Committees.,The appointment was effective February 21, 2008., ... Franco, Sr.,commented, "We are pleased that Haywood has joined ...
Cached Biology Technology:Vermillion Receives NASDAQ Notice of Non-Compliance 2Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 2Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 3Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 4Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 5Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 6Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 7Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 8Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 9Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 10Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results 11DARA BioSciences, Inc. Announces Appointment of New Director to Board 2
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)...   NexID Biometrics LLC, whose spoof-mitigation technology ... announced the beginning of shipments of version 2.0 of ... company, based in Potsdam, N.Y. , ... which began here today at the Walter E. Washington ... its SDK boosts the accuracy rate range to 96.5 ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 ... fraud case conviction losses. This figure accounts for a ... according to The Nilson Report, exceeds $11 billion globally. ... tool after a crime has occurred. Investor Mark ... polygraph expert Joe Paolella partnered to administer ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... A deep-sea mystery has been solved with the discovery that ... cod and mackerel, use the same buoyancy control as whales. ... Oceanography , researchers from British Antarctic Survey describe how Southern ... ,hibernates, in the deep ocean during winter when seas are ...
... sounds like something out of a comic book or a ... is exactly what two investigators at the Wellman Center for ... report that will appear in the journal Nature Photonics ... Gather, PhD, and Seok Hyun Yun, PhD, describe how a ...
... 14, 2010 Reportlinker.com announces that a new market ... Global Biochip Markets: Microarrays and Lab-on-a-Chip ... STUDY GOALS AND OBJECTIVES ... determine the status of current and emerging biochip technologies ...
Cached Biology News:Single GFP-expressing cell is basis of living laser device 2Single GFP-expressing cell is basis of living laser device 3Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 2Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 3Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 4Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 5Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 6Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 7Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 8Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 9Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 10Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 11Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 12Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 13Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 14Reportlinker Adds Global Biochip Markets: Microarrays and Lab-on-a-Chip 15
... is chromatographically purified from egg white. The extinction ... product is in 10 mM phosphate-buffered saline, ... albumin, 0.05% sodium azide and 50% glycerol. Avidin ... conjugate is purified by molecular sieving ...
in vitro Translation, Accessory Products...
Request Info...
... derivatives that have mutations in both the ... genes, which greatly enhances disulfide bond formation ... expression in Origami(DE3) yielded 10-fold more active ... overall expression levels were similar (1). Origami ...
Biology Products: